MDR3

Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

Retrieved on: 
Monday, November 13, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Sleep, Hepatology, MDR3, Self-harm, Safety, Hepatocellular carcinoma, Bilirubin, Cholestasis, AASLD, Liver, Disease, Risk, Cholestatic pruritus, Hematology, Quality of life (healthcare), MYO5B, PFIC, Patient, Publication, Pregnancy, Nature, TJP2, Ascending cholangitis, GI, Hippeastrum mirum, Liver support system, Volixibat, ICP, IBAT, Progressive familial intrahepatic cholestasis, FIC, Augmented fifth, Growth, Doctor of Philosophy, Quality of life, AND, Itch, Medication, MCID, HIV disease progression rates, SBA, Chloride, Pharmaceutical industry, Nursing, Medical imaging, Dietary supplement, Boston, BSEP

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced new data from its LIVMARLI and volixibat programs presented at The Liver Meeting®, the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, Massachusetts.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced new data from its LIVMARLI and volixibat programs presented at The Liver Meeting®, the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, Massachusetts.
  • “PFIC is a chronic, debilitating cholestatic liver disease characterized by elevated bile acids and pruritus so severe that patients can be listed for liver transplant even in the absence of disease progression.
  • These data suggest overall improved liver health with maralixibat treatment in patients with PFIC that can be maintained long-term.
  • No clinically meaningful changes in liver enzyme levels or hematology parameters were observed after volixibat treatment.

Worldwide Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Industry to 2027 - by Drug, Distribution Channel and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, July 16, 2021
Science, Research, Pharmaceutical, Surgery, General Health, Health, Genetics, Clinical trials, Medical specialties, Hepatology, Progressive familial intrahepatic cholestasis, Cholestasis, PFIC, Liver, ATP8B1, MDR3

The "Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare condition that affects the liver.
  • Increasing awareness about progressive familial intrahepatic cholestasis type 2 disease is expected to provide more opportunities for players in the progressive familial intrahepatic cholestasis type 2 treatment market in the near future.
  • Thus, low healthcare spending in low income countries limits such countries for research and development of new drugs for treatment of rare diseases.